Cargando…

The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus

Pretherapeutic identification of oesophageal squamous cell carcinomas that will respond to neoadjuvant chemoradiotherapy is an important attempt for improvement of patient's prognosis. In the current study, pretherapeutic biopsies from 94 oesophageal squamous cell carcinomas (cT3, cN0/+, cM0) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarbia, M, Ott, N, Pühringer-Oppermann, F, Brücher, B L D M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360233/ https://www.ncbi.nlm.nih.gov/pubmed/17940507 http://dx.doi.org/10.1038/sj.bjc.6604037

Ejemplares similares

Study of p53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus
por: Kaneko, K, et al.
Publicado: (2007)

Raman spectroscopy: elucidation of biochemical changes in carcinogenesis of oesophagus
por: Shetty, G, et al.
Publicado: (2006)

MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma
por: Fisher, O M, et al.
Publicado: (2015)

The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma
por: Sarbia, M, et al.
Publicado: (2006)

High expression of Lin28 is associated with tumour aggressiveness and poor prognosis of patients in oesophagus cancer
por: Hamano, R, et al.
Publicado: (2012)

Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus
por: Dunn, J M, et al.
Publicado: (2011)

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
por: Paliga, A, et al.
Publicado: (2012)

Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX
por: Nehls, O, et al.
Publicado: (2007)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

Downregulation of EGFR in hypoxic, diffusion-limited areas of squamous cell carcinomas of the head and neck
por: Mayer, Arnulf, et al.
Publicado: (2016)

Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response
por: Al-kaabi, M M, et al.
Publicado: (2015)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
por: Ruiz, M I Galleges, et al.
Publicado: (2009)

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
por: de Graeff, P, et al.
Publicado: (2009)

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels
por: Rondeau, S, et al.
Publicado: (2015)

Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma
por: Keller, J, et al.
Publicado: (2013)

The expression of p53-induced protein with death domain (Pidd) and apoptosis in oral squamous cell carcinoma
por: Bradley, G, et al.
Publicado: (2007)

Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy
por: Dunn, J M, et al.
Publicado: (2010)

Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma
por: Kobayashi, M, et al.
Publicado: (2012)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53
por: Meulendijks, D, et al.
Publicado: (2015)

Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma
por: Yuen, H-F, et al.
Publicado: (2007)

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
por: Rego, R L, et al.
Publicado: (2010)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer
por: Cui, T, et al.
Publicado: (2011)

Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
por: Takeshita, H, et al.
Publicado: (2010)

Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer
por: Leitch, E F, et al.
Publicado: (2007)

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
por: Jun, H J, et al.
Publicado: (2008)

Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma
por: Tanaka, N, et al.
Publicado: (2008)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue
por: Kauppila, J H, et al.
Publicado: (2013)

The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions
por: Terry, G, et al.
Publicado: (2007)

Targeting EGFR and PI3K pathways in ovarian cancer
por: Glaysher, S, et al.
Publicado: (2013)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

The prognostic significance of tumour cell proliferation in squamous cell carcinomas of the oesophagus.
por: Sarbia, M., et al.
Publicado: (1996)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation
por: Pan, D, et al.
Publicado: (2011)

HPV infection in squamous cell carcinomas arising from different mucosal sites of the head and neck region. Is p16 immunohistochemistry a reliable surrogate marker?
por: Bussu, F, et al.
Publicado: (2013)

CTL- vs T(reg) lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma
por: Liu, J Y, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_c9h5iruf07h91tjj716p66rpeg